Welcome to the Antibody Drug Conjugates Knowledge
Center. Antibody Drug Conjugates (ADCs) are
a new and technically challenging type of oncology therapy linking the fields
of biotechnology and chemistry.
Combining our expertise in mAbs and highly potent APIs with our ADC
know-how, Lonza helps create industry leading cancer therapies for our
customers. We are dedicated to sharing
our findings with other technical communities in order to advance ADC
development. Learn more about Lonza’s involvement
in this emerging technology in the below tabs.
To discover information regarding other areas of interest to you, visit
the Lonza Knowledge Center.
To reach our Antibody Drug Conjugates experts, email your
contact information and questions to email@example.com.
- Brochures, Posters, and Presentations